( IIIdevelopment as part of a collabora...)Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research,Health

S-1 is a novel oral fluoropyrimidine that combines three investigational agents: tegafur, a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine) which inhibits dihydropyrimidine dehydrogenase enzyme; and oteracil (potassium oxonate), a gastrointestinal side effect corrector. The Phase III data to be presented evaluate the addition of cisplatin to S-1 in advanced gastric cancer. S-1 is marketed in Japan by Taiho for a variety of indications including gastric cancer. Sanofi-aventis is leading the development of the compound outside of Japan and in some Asian countries.

TroVax(R) is a therapeutic cancer vaccine developed in collaboration with Oxford BioMedica. It targets the tumor antigen 5T4, broadly distributed in a wide range of solid tumors. The presentation will include new data from two Phase II trials of TroVax(R) in renal cancer.

Finally, the first outcomes of the innovative program "My Child Matters," a unique humanitarian pediatric cancer initiative in developing countries co- sponsored by sanofi-aventis and the International Union Against Cancer (UICC), will be presented.

Details on the key studies to be presented at the meeting during podium presentations and poster discussions are as follows:

Eloxatin(R) (oxaliplatin injection) clinical studies:

Abstract # 4007 - Oxaliplatin/5FU/LV in the adjuvant treatment of colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years.

    -- A long-term update including disease-free-survival and overall survival

       data from the MOSAIC study, which evaluates the role of

       oxaliplatin/5FU/LV (FOLFOX4) as adjuvant treatment for stage II and III

       colon cancer, will be presented.

    -- Sunday, June 3, 8:15 AM - 8:30 AM, E Arie Crown Theatre, Oral

       Presentation.

Abstract # 4067 - N9741:
'"/>